Theracos raises $25M to take on Big Pharma in diabetes

Marlborough, MA's Theracos raised $25 million to support its work on a safer version of a common treatment for Type 2 diabetes. As MedCity News reports, the company is at work on a drug that blocks a protein called SGLT2, diverting excess blood sugars out through the urine to harmonize patients' glucose levels. AstraZeneca ($AZN), Johnson & Johnson ($JNJ) and others already market SGLT2 therapies, but each has been marked by risks of urinary and genital infections. Theracos believes its agent, bexagliflozin, could provide a safer alternative with similar efficacy. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.